Head of Management Accounting

Company: 0750 Stemline Therapeutics Inc Contract Type: Permanent Join us in shaping the future of Menarini - with passion, integrity, and a deep commitment to people.

Menarini is a leading international biopharmaceutical company committed to advancing health through innovation, research, and quality. For more than 135 years, we have worked to improve patients’ lives across a broad range of therapeutic areas through our dedication to science, integrity, and care for people. With a strong foundation in scientific excellence and a purpose-driven culture, Menarini offers diverse career opportunities for professionals eager to make a meaningful impact on global health.

Director of Accounting

Reports to Associate VP of Finance

Opportunity The Director of Accounting is responsible for monthly general ledger close process, account analyses, financial reporting, analytical reviews, technical accounting research, treasury, among other activities. This role drives financial integrity by architecting robust internal controls, optimizing the end-to-end close process, and spearheading financial system enhancements. The ideal candidate is a collaborative, forward-thinking leader who leverages deep technical accounting expertise to deliver actionable financial insights, foster cross-functional partnerships, and align financial operations with overarching corporate strategy.

Financial Operations & Reporting Direct the preparation of comprehensive financial statements, ensuring strict adherence to month-end close schedules and executive-level accuracy for all adjustments and accruals. Govern the comprehensive management of general ledgers, accounts payable, revenue distribution, fixed assets, operating expenses, and insurance records. Manage cash flows working with Corporate HQ on cash needs and managing of cash balance via operations. Perform analytical review of financial results and understand factors driving variances.

Strategic Leadership & Partnership Cultivate strong, strategic partnerships across all business units, acting as a trusted advisor to cross-functional leaders to drive profitability and operational growth. Partner strategically with Corporate IT to champion and deploy financial system enhancements, driving automation and embedding best practices into enterprise architecture. Collaborate with tax leadership to ensure optimal tax strategy execution, providing critical financial insights and data for high-level tax initiatives. Spearhead high-impact strategic initiatives—enterprise software implementations and advanced management reporting—to support decision-making and continuous business improvement.

Compliance, Audit & Risk Management Architect and enforce best-in-class policies, procedures, and internal controls across accounting operations and financial management to mitigate risk and scale operations. Direct all interim and year-end audit engagements and compliance reviews, serving as the primary strategic liaison for external auditors. Lead complex technical accounting research, assessing the impact of new regulatory pronouncements and advising the executive team on strategic accounting implications.

Bachelor’s degree in Accounting MBA or CPA license is strongly preferred.

Experience in public accounting and/or pharmaceuticals industry is preferred

Experience in Gross to Net and Inventory accounting is strongly preferred

Minimum of 8-10 years of recent financial reporting or relevant audit experience, with at least 15 years of experience in Financial Accounting

Proficiency in Microsoft Office and SAP S4 HANA is preferred

Advanced knowledge of general accounting (US GAAP) Excellent analytical, problem solving and decision-making skills

Effective verbal, listening and written communication skills Effective organizational, stress and time management skills Ability to provide leadership and manage personnel Demonstrates a sense of urgency and ability to meet deadlines Ability to work independently or as a team member Ability to handle multiple tasks High level of personal and professional integrity.

Healthcare insurance

Company-paid Basic Life & AD&D insurance and pre-tax FSA/HSA programs

All qualified applicants will receive consideration for employment without regard to race, color, religion, sex, sexual orientation, gender identity, national origin, disability, or status as a protected veteran. Reasonable accommodations may be made to enable qualified individuals with disabilities to perform the essential functions.

The Company Founded in 1886 in Naples under the name of Farmacia Internazionale, Menarini moved in 1915 to Florence where the Group’s headquarters are still located today. High quality therapeutics and diagnostics solutions for patients, ethics as our underlying principle, dedication to innovation and advancement, strong people centricity and environmental sustainability. These five pillars form the foundation of the Menarini Group, an Italian pharmaceutical company with nearly 135 years of history. Its companies span from Europe to Asia, to Africa and the Middle East, to Central America and to the United States where with the acquisition of Stemline Therapeutics, a NASDAQ-listed biopharmaceutical company, the company marked its entry into the US oncology market. Thanks to the valuable contribution of around 18,000 employees, every year more than 500 million packs of drugs are produced at the Group's 18 manufacturing sites including a biotech plant for the manufacturing of monoclonal antibodies that also serves external clients distributed across 6 continents. Menarini has made a strong commitment to oncology, investing in a pipeline of five investigational compounds for the treatment of a variety of haematological and solid tumours. The acquisition of Stemline Therapeutics in June 2020, further strengthened Menarini’s oncology portfolio, adding both commercial and clinical-stage assets. Tagraxofusp is a novel, first in class targeted therapy for patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN) and to date, the only approved treatment for BPDCN in the U.S. and EU, and the first and only approved CD123-targeted therapy. Tagraxofusp is also being evaluated as both a single agent and in combination, in other CD123+ indications, including acute myeloid leukaemia (AML), chronic myelomonocytic leukaemia (CMML), and myelofibrosis (MF). Additionally, Menarini received exclusive rights to commercialise Selinexor for the treatment of oncology indications in the European Union and other European countries (including the United Kingdom), Latin America and other key countries. Selinexor is a first-in-class, oral Selective Inhibitor of Nuclear export compound for the treatment of hematologic cancers and solid tumours. It is already marketed in the US for multiple myeloma and is under development for solid tumour indications. Menarini entered into a global licence agreement with Radius Health to complete the development of Elacestrant, an oral SERD in late-stage Phase 3 development for hormone receptor-positive advanced breast cancer. Following a successful phase 3 study, Menarini Stemline received FDA approval in January 2023 under priority review and successfully oversaw a strong launch in February to the US market with the EMA review process concluded positively in September 2023. Menarini’s commitment to oncology is also reflected in the investments made in the liquid biopsy diagnostic field through its affiliate Menarini Silicon Biosystems (MSB), a pioneer in rare cell analysis and non-invasive, advanced diagnostic solutions. Food & Drug Administration (FDA) for detecting and counting CTCs in metastatic breast, prostate, and colorectal cancer when used in conjunction with other clinical monitoring methods. Since 2021, MSB has offered in the US a menu of non-invasive Laboratory Developed Tests (LDTs) provided through its CLIA/CAP accredited US-based Lab. This test provides new, complementary information to that of the bone marrow biopsy and other standard-of-care measures. Menarini's vision and uniqueness in oncology is to bring together innovative therapeutic solutions and advanced liquid biopsy-based diagnostics for faster, more effective and precise patient management. It is an exciting time in the company’s development and an excellent opportunity for individuals joining us to contribute to building and shaping Menarini Stemline's Oncology business. For more details on how we handle your data, please refer to our Privacy Policy. Become part of a story that began in 1886 with a small pharmacy in Naples and has grown into a global presence in over 140 countries, improving lives through innovative medicines, diagnostics, and healthcare solutions. At Menarini, you're not just building a career-you’re making a real impact. We put people first-patients and employees alike- and foster a culture where ideas are valued, growth is supported, and the future of health is shaped together. Together, we make health a lifelong commitment.

#